12
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Effect of a drug combination treatment on ocular perfusion in recurrent idiopathic intermediate uveitis

, , , , &
Pages 299-303 | Published online: 08 Jul 2009
 

Abstract

Purpose: To test the effect of a drug combination therapy on ocular perfusion in human eyes affected by idiopathic intermediate uveitis. Methods: Seven patients (12 eyes) showing active signs of intermediate uveitis, with at least two more similar episodes reported within the previous 12 months, were enrolled in a prospective case series. Two fellow healthy eyes of two of the enrolled patients were studied as internal controls. Color Doppler imaging of the central retinal artery (CRA), the ophthalmic artery (OA), and the posterior ciliary arteries (PCAs) was performed at the time of enrollment, and at 6 and 12 months after starting treatment with oral fluorocortolone, cyclosporine, and parenteral methotrexate. The best-corrected visual acuity was concurrently measured as a second parameter. Results: In the 12 affected eyes, the mean visual acuity (±SD) improved from 0.15(±0.12) to 0.04(±0.18) LogMAR (paired samples Student’s t -test: p = 0.015). The resistivity index (RI ± SD) of the CRA decreased from 0.81(±0.13) to 0.71(±0.13)(p = 0.0091). Further, the variation of the RI in the PCAs reached a borderline significance (p = 0.062), decreasing from 0.71(±0.12) to 0.61(±0.12). No significant changes were observed in the OA. Moreover, eyes showing a visual improvement of =.01 (LogMAR) were more likely to show a =10% improvement of the RI for the CRA (Fisher’s exact test: p = 0.018; power = 90%; alpha probability = 5%; odds ratio = 2,4). Conclusions: In eyes affected by idiopathic intermediate uveitis, treated with a systemic drug combination therapy, the improvement of the visual acuity seems to correlate with a proportional improvement of the retrobulbar circulation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.